A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Bera, Alakesh ^a   VenkataSubbaRao, Kolaparthi ^a   Manoharan, Muthu Saravanan ^c   Hill, Ping ^a   Freeman, James W ^a,b,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; HERMES ANTIGEN; MICRORNA; MICRORNA 100; MICRORNA 1246; MICRORNA 125B; MICRORNA 155; MICRORNA 15B; MICRORNA 205; MICRORNA 21; MICRORNA 25; MICRORNA 27B; MICRORNA 30D; MICRORNA 378; MICRORNA 424; MICRORNA 4324; MICRORNA 4443; MICRORNA 4485; MICRORNA 455 3P; MICRORNA 99B; PROTEIN BCL 2; PUMA PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; DEOXYCYTIDINE; MIRN125 MICRORNA, HUMAN; NEU1 PROTEIN, HUMAN; ONCOPROTEIN; SIALIDASE; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; ASPC 1 CELL LINE; BAP1 GENE; BBC3 GENE; BCL2 GENE; BXPC3 CELL LINE; CANCER RESISTANCE; CAPAN 2 CELL LINE; CELL POPULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; NEU1 GENE; PANC 1 CELL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; RNA SEQUENCE; STARD13 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MESODERM; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREAS CARCINOMA; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESODERM; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEURAMINIDASE; PROTO-ONCOGENE PROTEINS;

EID: 84906963744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106343     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, et al. (2008) Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res 14: 3529-3535.
3. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, et al. (2011) Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33.
4. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
5. Van den Broeck A, Gremeaux L, Topal B, Vankelecom H (2012) Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 12: 354.
6. Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746.
7. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
8. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
9. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, et al. (2012) Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 72: 3393-3404.
10. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, et al. (2012) Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One 7: e40021.
11. Danquah M, Singh S, Behrman SW, Mahato RI (2012) Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opin Drug Deliv 9: 1443-1447.
12. Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914.
13. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793.
14. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907.
15. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, et al. (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407.
16. Singh S, Chitkara D, Kumar V, Behrman SW, Mahato RI (2013) miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 334: 211-220.
17. Zhao S, Ammanamanchi S, Brattain M, Cao L, Thangasamy A, et al. (2008) Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. J Biol Chem 283: 11293-11301.
18. Bera A, Zhao S, Cao L, Chiao PJ, Freeman JW (2013) Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. PLoS One 8: e82282.
19. Venkatasubbarao K, Choudary A, Freeman JW (2005) Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res 65: 2861-2871.
20. Hu HY, Guo S, Xi J, Yan Z, Fu N, et al. (2011) MicroRNA expression and regulation in human, chimpanzee, and macaque brains. PLoS Genet 7: e1002327.
21. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, et al. (2012) Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One 7: e34150.
22. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.
23. Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, et al. (2014) Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Target Oncol. DOI 10.1007/s11523-014-0323-z
24. Dong J, Zhao YP, Zhou L, Zhang TP, Chen G (2011) Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 42: 8-14.
25. Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196.
26. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubuletargeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066.
27. Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, et al. (2014) Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 33: 702-712.
28. Le MT, Shyh-Chang N, Khaw SL, Chin L, Teh C, et al. (2011) Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet 7: e1002242.
29. Le MT, Xie H, Zhou B, Chia PH, Rizk P, et al. (2009) MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 29: 5290-5305.
30. Tang F, Zhang R, He Y, Zou M, Guo L, et al. (2012) MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One 7: e35435.
31. Yang S, Sun W, Zhang F, Li Z (2013) Phylogenetically diverse denitrifying and ammonia-oxidizing bacteria in corals Alcyonium gracillimum and Tubastraea coccinea. Mar Biotechnol (NY) 15: 540-551.
32. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694.
33. Yu J, Zhang L (2008) PUMA, a potent killer with or without p53. Oncogene 27 Suppl 1: S71-83.
34. Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, et al. (2009) Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene 28: 1218-1229.
35. O'Shea LK, Abdulkhalek S, Allison S, Neufeld RJ, Szewczuk MR (2014) Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu(R)) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther 7: 117-134.
36. Collins AT, Maitland NJ (2006) Prostate cancer stem cells. Eur J Cancer 42: 1213-1218.
37. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, et al. (2009) Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065-4074.
38. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, et al. (2013) A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A 110: 9845-9850.
39. Li Y, VandenBoom TG, 2nd, Kong D, Wang Z, Ali S, et al. (2009) Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712.
40. Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726.
41. Peter ME (2009) Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8: 843-852.
42. Cui EH, Li HJ, Hua F, Wang B, Mao W, et al. (2013) Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 34: 309-313.
43. Wang H, Tan G, Dong L, Cheng L, Li K, et al. (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7: e34210.
44. Yuxia M, Zhennan T, Wei Z (2012) Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 138: 2045-2050.
45. Wang L, Zhang D, Zhang C, Zhang S, Wang Z, et al. (2012) A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer. Oncol Lett 3: 119-124.
46. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE (2012) miR-125b targets ARID3B in breast cancer cells. Cell Struct Funct 37: 27-38.
47. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, et al. (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282: 1479-1486.
48. Huang L, Luo J, Cai Q, Pan Q, Zeng H, et al. (2011) MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 128: 1758-1769.
49. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, et al. (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting proapoptotic genes. Prostate 71: 538-549.
50. Chen Y, Qian H, Wang H, Zhang X, Fu M, et al. (2007) Ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents. Gynecol Oncol 107: 505-512.